Phase 1 Study of MP101 in Adults With Acute Pseudomonas aeruginosa Pneumonia

A randomized, double-blind, placebo-controlled phase 1 study to evaluate the safety, tolerability and pharmacokinetics and pharmacodynamics of MP101 in adult patients with acute Pseudomonas aeruginosa pneumonia

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

CRIS

Registry ID

KCT0011717

Enrollment

Registered

2026-03-12

Start date

2026-03-20

Completion date

Unknown

Last updated

2026-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Biological/Vaccine, Non-Stem Cell : This clinical trial is a Phase 1 study with a randomized, double-blind, placebo-controlled, single-dose, sequential dose-escalation design and consists of two dos

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Subjects diagnosed with acute pneumonia 2. Subjects confirmed to be non-susceptible to the antibiotics currently being administered

Exclusion criteria

Exclusion criteria: Subjects with non-bacterial pneumonia, etc.

Design outcomes

Primary

Measure	Time frame
Incidence and frequency of adverse events (AEs), adverse drug reactions (ADRs), serious adverse events (SAEs), and serious adverse drug reactions (SADRs) occurring after administration of MP101.	—

Secondary

Measure	Time frame
Assessment of the pharmacokinetic (PK) characteristics of MP101	—

Countries

Korea, Republic of

Contacts

Public ContactJun Yong Choi

Yonsei University Health System, Severance Hospital

seran@yuhs.ac+82-2-2228-1974

Outcome results